BDSX News and Press, Biodesix Inc. From 03/07/22

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced it has entered into a purchase agreement for the issuance and sale of its common stock, from time to time, of up to $50 million with Lincoln Park Capital F...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting. In this body of work, the PIR test provid...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present at Cowen’s 42nd Annual Healthcare Conference being held virtually March 7-9, 2022. ...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021 before the open of trading on Monday, March 14. Biodesix...

Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that its Chief Executive Officer was named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022. The annual list recognizes the most...

Biodesix (NASDAQ:BDSX) expects Q4 and FY21 revenue to be ~$7.2M and $54.5M (compared to $45.6M in 2020) respectively; growth led by company's core lung diagnostic testing and 1H21 COVID-19 testing. Analysts consensus estimates for Q4 and FY21 revenue stood at $7.23M and $54.48M respectively. ...

Core lung diagnostic testing revenues grow 49% for full-year 2021 Biodesix, Inc. (NASDAQ: BDSX) a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Company expects to report fourth quarter and record full-year 2021 prelim...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will present in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools...

Partnership enables comprehensive clinical information to deliver optimal patient care PierianDx, the global leader in clinical genomics knowledge, today announced that it has partnered with Biodesix to provide its interpretation technology platform for use with the Biod...

Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced...